Status:
COMPLETED
Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide
Lead Sponsor:
Chinese Academy of Sciences
Conditions:
Healthy
Eligibility:
MALE
21-27 years
Brief Summary
The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.
Detailed Description
Compared with CYP2C19, CYP2C9 polymorphism appears to have a dominant role in glipizide pharmacokinetics and pharmacodynamics in vivo. This indicated that dose adjustment based on CYP2C9 genotype may ...
Eligibility Criteria
Inclusion
- nonsmokers and in good health
Exclusion
- family history of diabetes mellitus
- taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before study
Key Trial Info
Start Date :
August 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00806013
Start Date
August 1 2008
End Date
December 1 2008
Last Update
January 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The second hospital to Liaoning University of TCM
Shenyang, Liaoning, China, 201203